Bret J. Musser

5.3k total citations
24 papers, 1.3k citations indexed

About

Bret J. Musser is a scholar working on Pharmacology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, Bret J. Musser has authored 24 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pharmacology, 7 papers in Endocrinology, Diabetes and Metabolism and 4 papers in Surgery. Recurrent topics in Bret J. Musser's work include Pharmacology and Obesity Treatment (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Regulation of Appetite and Obesity (4 papers). Bret J. Musser is often cited by papers focused on Pharmacology and Obesity Treatment (4 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Regulation of Appetite and Obesity (4 papers). Bret J. Musser collaborates with scholars based in United States, Finland and Germany. Bret J. Musser's co-authors include Keith D. Kaufman, John M. Amatruda, Samuel S. Engel, Michael J. Davies, Debora Williams‐Herman, Elizabeth Round, Steven B. Heymsfield, Hua Guo, Barry J. Goldstein and Jeremy Johnson and has published in prestigious journals such as Nature Communications, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Bret J. Musser

23 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bret J. Musser United States	14	689	271	258	257	234	24	1.3k
Prajakti A. Kothare United States	22	1.1k 1.6×	330 1.2×	480 1.9×	601 2.3×	138 0.6×	35	1.8k
Curtis J. Rosebraugh United States	16	588 0.9×	237 0.9×	281 1.1×	279 1.1×	212 0.9×	24	1.3k
Gianluca Bardini Italy	20	1.1k 1.5×	112 0.4×	491 1.9×	432 1.7×	237 1.0×	40	1.6k
Sof Andrikopoulos Australia	20	471 0.7×	82 0.3×	530 2.1×	504 2.0×	441 1.9×	25	1.5k
Masato Odawara Japan	25	923 1.3×	160 0.6×	642 2.5×	419 1.6×	148 0.6×	112	1.9k
Serge Halimi France	21	832 1.2×	97 0.4×	260 1.0×	255 1.0×	312 1.3×	63	1.9k
Eric Colman United States	11	225 0.3×	274 1.0×	128 0.5×	132 0.5×	325 1.4×	15	836
Lars Hansen Denmark	27	1.2k 1.7×	131 0.5×	864 3.3×	822 3.2×	306 1.3×	55	2.3k
Charlie Cao United States	13	489 0.7×	75 0.3×	321 1.2×	275 1.1×	85 0.4×	25	1.4k
Gillian Shepherd United States	14	387 0.6×	751 2.8×	121 0.5×	204 0.8×	443 1.9×	26	1.4k

Countries citing papers authored by Bret J. Musser

Since Specialization

Citations

This map shows the geographic impact of Bret J. Musser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bret J. Musser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bret J. Musser more than expected).

Fields of papers citing papers by Bret J. Musser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bret J. Musser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bret J. Musser. The network helps show where Bret J. Musser may publish in the future.

Co-authorship network of co-authors of Bret J. Musser

This figure shows the co-authorship network connecting the top 25 collaborators of Bret J. Musser. A scholar is included among the top collaborators of Bret J. Musser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bret J. Musser. Bret J. Musser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Trotter, Dinko González, Stephen Donahue, Chris Wynne, et al.. (2025). GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial. Nature Communications. 16(1). 4376–4376. 2 indexed citations

Trotter, Dinko González, Jennifer McGinniss, Kusha Mohammadi, et al.. (2024). Comparison of PET/CT versus CT only in the assessment of new heterotopic ossification bone lesions in patients with fibrodysplasia ossificans progressiva. Bone. 190. 117280–117280.

O’Brien, Meagan P., Andrea T. Hooper, Eduardo Forleo‐Neto, et al.. (2023). Nasopharyngeal Viral Load Is the Major Driver of Incident Antibody Immune Response to SARS-CoV-2 Infection. Open Forum Infectious Diseases. 10(12). ofad598–ofad598. 1 indexed citations

Hooper, Andrea T., Diana Rofail, Kusha Mohammadi, et al.. (2023). Casirivimab + imdevimab accelerates symptom resolution linked to improved COVID-19 outcomes across susceptible antibody and risk profiles. Scientific Reports. 13(1). 12784–12784. 3 indexed citations

Geba, Gregory P., et al.. (2022). Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. Journal of Allergy and Clinical Immunology. 151(3). 756–766. 57 indexed citations

Sivapalasingam, Sumathi, George A. Saviolakis, Kirsten Kulcsar, et al.. (2021). Human Monoclonal Antibody Cocktail for the Treatment or Prophylaxis of Middle East Respiratory Syndrome Coronavirus. The Journal of Infectious Diseases. 225(10). 1765–1772. 3 indexed citations

Musser, Bret J., James A. Bolognese, Yue Shentu, et al.. (2014). Early Clinical Development Planning via Biomarkers, Clinical Endpoints, and Simulation: A Case Study to Optimize for Phase 3 Dose Selection. Therapeutic Innovation & Regulatory Science. 49(3). 405–414. 1 indexed citations

Peng, Joanna, William S. Denney, Bret J. Musser, et al.. (2014). A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adaptive Phase II Design. The AAPS Journal. 16(6). 1259–1270. 15 indexed citations

Aravind, S. R., Shaiful Bahari Ismail, Naim Shehadeh, et al.. (2011). Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study. Current Medical Research and Opinion. 27(6). 1237–1242. 75 indexed citations

10.

Williams‐Herman, Debora, Samuel S. Engel, Elizabeth Round, et al.. (2010). Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocrine Disorders. 10(1). 7–7. 215 indexed citations

11.

Cartwright, Mark E., Joseph C. Fleishaker, Sedigheh Madani, et al.. (2010). Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice. Clinical Pharmacology & Therapeutics. 87(3). 278–285. 42 indexed citations

12.

Vilsbøll, Tina, Julio Rosenstock, H Yki-Järvinen, et al.. (2009). Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes. Diabetes Obesity and Metabolism. 12(2). 167–177. 253 indexed citations

13.

Elobeid, Mai, Miguel A. Padilla, Olivia Thomas, et al.. (2009). Missing Data in Randomized Clinical Trials for Weight Loss: Scope of the Problem, State of the Field, and Performance of Statistical Methods. PLoS ONE. 4(8). e6624–e6624. 131 indexed citations

14.

Schwartz, Jules I., Nancy Agrawal, Martin Wehling, et al.. (2008). Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. British Journal of Clinical Pharmacology. 66(6). 811–817. 12 indexed citations

15.

Williams‐Herman, Debora, Elizabeth Round, Arlene S. Swern, et al.. (2008). Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. BMC Endocrine Disorders. 8(1). 14–14. 106 indexed citations

16.

Erondu, Ngozi, Carol Addy, Kaifeng Lu, et al.. (2007). NPY5R Antagonism Does Not Augment the Weight Loss Efficacy of Orlistat or Sibutramine. Obesity. 15(8). 2027–2042. 23 indexed citations

17.

Gantz, Ira, Ngozi Erondu, Madhuja Mallick, et al.. (2007). Efficacy and Safety of Intranasal Peptide YY3–36 for Weight Reduction in Obese Adults. The Journal of Clinical Endocrinology & Metabolism. 92(5). 1754–1757. 124 indexed citations

18.

Erondu, Ngozi, Thomas A. Wadden, Ira Gantz, et al.. (2007). Effect of NPY5R Antagonist MK‐0557 on Weight Regain after Very‐low‐calorie Diet‐induced Weight Loss. Obesity. 15(4). 895–905. 47 indexed citations

19.

Agrawal, Nancy, Arturo G. Porras, Catherine Z. Matthews, et al.. (2003). Single‐ and Multiple‐Dose Pharmacokinetics of Etoricoxib, a Selective Inhibitor of Cyclooxygenase‐2, in Man. The Journal of Clinical Pharmacology. 43(3). 268–276. 70 indexed citations

20.

Prueksaritanont, Thomayant, José María Guerrero Vega, Jamie J. Zhao, et al.. (2001). Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects. The Journal of Clinical Pharmacology. 41(5). 573–581. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact